Int J Biol Sci 2023; 19(11):3360-3382. doi:10.7150/ijbs.83026 This issue Cite

Review

Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer

Yuqing Lu1#, Yuewen Yang1#, Guanghao Zhu2#, Hairong Zeng2, Yiming Fan3, Fujia Guo1, Dongshu Xu1, Boya Wang1, Dapeng Chen1✉, Guangbo Ge2✉

1. Dalian Medical University, 116044 Dalian City, Liaoning Province, China.
2. Shanghai University of Traditional Chinese Medicine, 201203 Shanghai City, China.
3. Dalian Harmony Medical Testing Laboratory Co., Ltd, 116620 Dalian City, Liaoning Province, China.
#Equal contribution

Citation:
Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Int J Biol Sci 2023; 19(11):3360-3382. doi:10.7150/ijbs.83026. https://www.ijbs.com/v19p3360.htm
Other styles

File import instruction

Abstract

Graphic abstract

Targeted therapies in cancer treatment can improve in vivo efficacy and reduce adverse effects by altering the tissue exposure of specific biomolecules. However, there are still large number of target proteins in cancer are still undruggable, owing to the following factors including (1) lack of ligand-binding pockets, (2) function based on protein-protein interactions (PPIs), (3) the highly specific conserved active sites among protein family members, and (4) the variability of tertiary docking structures. The current status of undruggable targets proteins such as KRAS, TP53, C-MYC, PTP, are carefully introduced in this review. Some novel techniques and drug designing strategies have been applicated for overcoming these undruggable proteins, and the most classic and well-known technology is proteolysis targeting chimeras (PROTACs). In this review, the novel drug development strategies including targeting protein degradation, targeting PPI, targeting intrinsically disordered regions, as well as targeting protein-DNA binding are described, and we also discuss the potential of these strategies for overcoming the undruggable targets. Besides, intelligence-assisted technologies like Alpha-Fold help us a lot to predict the protein structure, which is beneficial for drug development. The discovery of new targets and the development of drugs targeting them, especially those undruggable targets, remain a huge challenge. New drug development strategies, better extraction processes that do not disrupt protein-protein interactions, and more precise artificial intelligence technologies may provide significant assistance in overcoming these undruggable targets.

Keywords: Cancer, Undruggable target, Protein-protein interaction, Intrinsically disordered protein, Targeted protein degradation, Proteolysis targeting chimera


Citation styles

APA
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., Ge, G. (2023). Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. International Journal of Biological Sciences, 19(11), 3360-3382. https://doi.org/10.7150/ijbs.83026.

ACS
Lu, Y.; Yang, Y.; Zhu, G.; Zeng, H.; Fan, Y.; Guo, F.; Xu, D.; Wang, B.; Chen, D.; Ge, G. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Int. J. Biol. Sci. 2023, 19 (11), 3360-3382. DOI: 10.7150/ijbs.83026.

NLM
Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Int J Biol Sci 2023; 19(11):3360-3382. doi:10.7150/ijbs.83026. https://www.ijbs.com/v19p3360.htm

CSE
Lu Y, Yang Y, Zhu G, Zeng H, Fan Y, Guo F, Xu D, Wang B, Chen D, Ge G. 2023. Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer. Int J Biol Sci. 19(11):3360-3382.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image